sunRIZE Phase 3 Misses Primary Endpoint in Congenital Hyperinsulinism
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute's sunRIZE trial in congenital hyperinsulinism missed its primary endpoint, a clear setback for the lead program. Management points to fewer hypoglycemia events on several continuous glucose monitoring measures, but a missed primary endpoint is what regulators and investors weigh first. The company reported $108 million in cash, enough to fund operations through the first quarter of 2028, so near-term financing risk is limited even as the sunRIZE path forward is now uncertain. This follows the October 5 disclosure that the FDA recommended a Type B pre-BLA meeting for ersodetug in congenital HI after reviewing sunRIZE data, and the October 14 completion of enrollment in the Phase 3 upLIFT tumor HI study, whose topline results are pending. The December 2 annual meeting vote on raising authorized common stock from 165 million to 225 million shares remains a separate overhang.
At the time of this announcement, RZLT was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $382.1M. The 52-week trading range was $1.07 to $11.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.